Discover and read the best of Twitter Threads about #PYC
Most recents (1)
For a long time I thought computational drug modelling really had only one listed company: $SLP
Turns out maybe not: Physiomics #PYC could be a decent candidate for a comp.
Growth is inflecting, it has optionalities and thanks to AIM obscurity it's on a fwd EV/Sales of 6.5x
Turns out maybe not: Physiomics #PYC could be a decent candidate for a comp.
Growth is inflecting, it has optionalities and thanks to AIM obscurity it's on a fwd EV/Sales of 6.5x
I first bought $SLP in April 2013. I mention this to make the point that was long before the current bubble in futuristic healthcare stocks, or before SaaS was a thing, this was already a punishingly expensive sector.
Here are the multiples you would've seen back then
Here are the multiples you would've seen back then
Now, $SLP and #PYC are similar but not the same.
SLP was pure software to model drug absorption, sold on licence. It had incredible margins but slow, steady growth. In 2013 it did $10M in revs and in the most recent like-for-like split, FY19, it did $20: ~+10% a year or so
SLP was pure software to model drug absorption, sold on licence. It had incredible margins but slow, steady growth. In 2013 it did $10M in revs and in the most recent like-for-like split, FY19, it did $20: ~+10% a year or so
